The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO.sub.2—; R.sup.1 is a C.sub.1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R.sup.1 is not a C.sub.1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X.sub.1 is —CRa═ or —N═; X.sub.2 is —CRb═ or —N═; X.sub.3 is —CRc= or —N═; Ra, Rb and Rc are each a C.sub.1-6 alkyl group, C.sub.2-6 alkenyl group, C.sub.1-6 alkoxy group, C.sub.3-6 cycloalkyl group, C.sub.3-6 cycloalkoxy group or C.sub.6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula ##STR00001##
wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO.sub.2—; R.sup.1 is a C.sub.1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R.sup.1 is not a C.sub.1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X.sub.1 is —CRa═ or —N═; X.sub.2 is —CRb═ or —N═; X.sub.3 is —CRc= or —N═; Ra, Rb and Rc are each a C.sub.1-6 alkyl group, C.sub.2-6 alkenyl group, C.sub.1-6 alkoxy group, C.sub.3-6 cycloalkyl group, C.sub.3-6 cycloalkoxy group or C.sub.6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.

The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.